University Hospitals - Seidman Cancer Center
Welcome,         Profile    Billing    Logout  
 24 Trials 
26 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Richard K
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
NCT04824937: Telaglenastat + Talazoparib In Prostate Cancer

Not yet recruiting
2
30
US
Telaglenastat, CB 839, Talazoparib, Taken orally
Massachusetts General Hospital, Calithera Biosciences, Inc, Pfizer, Prostate Cancer Foundation
Prostate Cancer Metastatic
12/21
12/21
KEYNOTE B36, NCT04892472: EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
2
100
US
NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg
NovoCure GmbH, Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
07/24
12/26
NCT04014205: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Active, not recruiting
1/2
81
Europe, US, RoW
Orelabrutinib (ICP-022)
Beijing InnoCare Pharma Tech Co., Ltd.
Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
12/23
01/25
CELLO-1, NCT04179864 / 2019-003649-14: A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

Checkmark Data from CELLO-1 trial for CRPC at SUO 2022
Dec 2022 - Dec 2022: Data from CELLO-1 trial for CRPC at SUO 2022
Checkmark Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
Sep 2021 - Sep 2021: Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
Terminated
1/2
102
Europe, US
Tazemetostat, EPZ-6438, E7438, IPN60200, Abiraterone/prednisone, Zytiga, Enzalutamide, Xtandi
Epizyme, Inc.
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
11/24
11/24
KEYNOTE-E58, NCT04041310: Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Active, not recruiting
1/2
115
Europe, Canada, US
GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab
Nouscom SRL, Merck Sharp & Dohme LLC
Solid Tumor, Adult
04/25
11/26
NCT04524962: Study of Descartes-30 in Acute Respiratory Distress Syndrome

Terminated
1
12
US
Descartes 30
Cartesian Therapeutics, National Heart, Lung, and Blood Institute (NHLBI)
Acute Respiratory Distress Syndrome, Covid19
09/22
09/23
SCOOT, NCT05368298: Sample Collection for DART

Recruiting
N/A
5000
Europe
University of Oxford, Innovate UK, Optellum, National Institute for Health Research, United Kingdom, Cancer Research UK, GE Healthcare, RNA Guardian, Roche Diagnostics GmbH
Lung Cancer
02/25
02/25
AnswerLine, Cancer
NCT04845035: Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Withdrawn
2
23
US
Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy, Methotrexate and Cytarabine
University of Michigan Rogel Cancer Center, Takeda
Acute Lymphoblastic Leukemia
01/26
01/29
AVB500-PC-005, NCT04983407: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Terminated
1b/2
34
US
batiraxcept, AVB-S6-500, Nab paclitaxel, Abraxane, Gemcitabine
Aravive, Inc.
Pancreatic Adenocarcinoma
08/23
08/23
NCT03520075 / 2018-004568-72: Study of ASTX029 in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
190
Europe, US
ASTX029
Taiho Oncology, Inc.
Solid Tumor, Adult
08/24
12/25
NCT03559049: Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Active, not recruiting
1/2
25
US
Pembrolizumab, Pemetrexed, Carboplatin, Rucaparib
University of Michigan Rogel Cancer Center, Merck Sharp & Dohme LLC, Clovis Oncology, Inc.
Stage IV Non-small Cell Lung Cancer
01/25
01/28
CAPS, NCT03781986: APG-115 in Salivary Gland Cancer Trial

Active, not recruiting
1/2
41
US
APG-115, Carboplatin
University of Michigan Rogel Cancer Center, Ascentage Pharma Group Inc.
Malignant Salivary Gland Cancer, Salivary Gland Cancer
06/25
12/25
NCT06616155: Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Not yet recruiting
1/2
39
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Enzalutamide, ASP9785, MDV 3100, MDV-3100, MDV3100, Xtandi, Ruxolitinib, INCB 018424, INCB-018424, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424
University of Michigan Rogel Cancer Center, Incyte Corporation
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
03/27
03/29
NCT05902988: A Phase I/II Study of VLS-1488 in Subjects with Advanced Cancer

Recruiting
1/2
120
US
VLS-1488
Volastra Therapeutics, Inc.
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Transitional Cell Carcinoma of Bladder, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
12/25
06/26
LiFFT, NCT05918640: Lurbinectedin in FET-Fused Tumors

Recruiting
1/2
56
US
Lurbinectedin
Children's Hospital of Philadelphia, Jazz Pharmaceuticals, Stand Up To Cancer
Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
07/26
07/28
ASCLEPIuS, NCT04194554: A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Active, not recruiting
1/2
102
US
Niraparib, Leuprolide, Abiraterone Acetate, Stereotactic body radiotherapy (SBRT), Ultra-hypofractionated radiotherapy
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC
Prostate Cancer
11/26
05/27
NCT04703920: Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Active, not recruiting
1
26
US
Talazoparib, Belinostat
University of Michigan Rogel Cancer Center, Pfizer, Acrotech Biopharma Inc.
Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma
12/24
12/24
NCT00843375: Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas

Recruiting
N/A
1200
Canada, US, RoW
University of Michigan Rogel Cancer Center, Early Detection Research Network, Clinical Genomics Pathology, VolitionRx, Department of Health and Human Services, Great Lakes New England Clinical Validation Center, National Cancer Institute (NCI)
Colonic Neoplasms
03/28
03/28
Bajor, David
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
TOS-358-001, NCT05683418: A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults with Select Solid Tumors

Recruiting
1
241
Europe, US
TOS-358
Totus Medicines
Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, HR+/HER2-negative Breast Cancer
12/25
12/25
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
SGNEGFRd2-001, NCT05983133: A Study of SGN-EGFRd2 in Advanced Solid Tumors

Recruiting
1
275
Europe, US
SGN-EGFRd2
Seagen Inc.
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
07/27
09/28
Barata, Pedro
NCT05588609: Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Active, not recruiting
2
90
US
Afatinib Oral Tablet, GILOTRIF®, GIOTRIF®, Enzalutamide Pill, XTANDI®, Abiraterone acetate tablets, ZYTIGA®, MCLA-128, Zenocutuzumab
Merus N.V.
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
10/25
03/26
NCT04267120: Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Active, not recruiting
2
11
US
Lenvatinib, Lenvima, Lenvanix, Pembrolizumab, Keytruda, MK-3475, Research blood collection
Washington University School of Medicine, Merck Sharp & Dohme LLC
Renal Cell Carcinoma
07/24
12/25
CC, UH Seidman
No trials found

Download Options